Document is current
Any future updates will be listed below
-
Authors
Bexte, Tobias https://orcid.org/0009-0009-2392-6416
Albinger, Nawid
Al Ajami, Ahmad
Wendel, Philipp https://orcid.org/0000-0001-5844-1587
Buchinger, Leon
Gessner, Alec
Alzubi, Jamal https://orcid.org/0000-0003-4284-2006
Särchen, Vinzenz https://orcid.org/0000-0001-9565-2850
Vogler, Meike https://orcid.org/0000-0003-2650-586X
Rasheed, Hadeer Mohamed https://orcid.org/0000-0003-1010-296X
Jung, Beate Anahita
Wolf, Sebastian
Bhayadia, Raj https://orcid.org/0000-0003-0865-9582
Oellerich, Thomas
Klusmann, Jan-Henning https://orcid.org/0000-0002-1070-0727
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Möker, Nina
Cathomen, Toni https://orcid.org/0000-0002-7757-4630
Rieger, Michael A. https://orcid.org/0000-0002-4158-5872
Imkeller, Katharina
Ullrich, Evelyn https://orcid.org/0000-0001-8530-1192
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 30 August 2024
First Online: 30 September 2024
Competing interests
: E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT/EP2024/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.
